Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2011-05-10
2011-05-10
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C514S007600, C514S012200, C514S109000
Reexamination Certificate
active
07939052
ABSTRACT:
Administration of U-II to rats caused an increase in the redness or the skin temperature of the ear of the rats. The increase was inhibited by compounds that decease the biological activity of the U-II/UT receptor. Thus, the present invention provides methods of measuring the biological activity of an U-II receptor by monitoring the redness or the skin temperature of the ear of an animal, and the use of the methods to test compounds for their abilities to increase or decrease the biological activity of an U-II receptor.
REFERENCES:
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 2003/0216407 (2003-11-01), Butt et al.
patent: 2004/0077529 (2004-04-01), Lehmann et al.
patent: 2005/0075480 (2005-04-01), Coy et al.
Sheila A Doggrell, Urotensin-II and the cardiovasuclar system—the importance of developing modulators, Expert. Opin. Investig. Drugs (2004, 13(5), 479-487.
Jennifer L. Davison, Daniel S. Short and Thad E. Wilson, Effect of local heating and vasodilation on the cutaneous venoarteriolar response, Clin Auton res. (2004), 14, 385-390.
Ames, et al., “Human Urotensin-II is a Potent Vasoconstrictor and Agonist for the Orphan Receptor GPR14”, Nature, 1999, 401(6750), pp. 282-286.
Bottrill, et al., “Human Urotensin-II is an Endothelium-Dependent Vasodilator in Rat Small Arteries”, British Journal of Pharmacology, 2000, 130(8), pp. 1865-1870.
Camarda, et al., “Urantide Mimics Urotensin-II Induced Calcium Release in Cells Expressing Recombinant UT Receptors”, European Journal of Pharmacology, 2004, 498(1-3), pp. 83-86.
Conlon et al., “Distribution and Molecular Forms of Urotensin II and its Role in Cardiovascular Regulation in Vertebrates”, The Journal of Experimental Zoology, 1996, 275, pp. 226-238.
Coulouarn et al., “Cloning of the cDNA Encoding the Urotensin II Precursor in Frog and Human Reveals Intense Expression of the Urotensin II Gene in Motoneurons of the Spinal Cord”, Procedural National Academy of Science USA, 1998, 95, pp. 15803-15808.
Coulouarn et al., “Cloning, Sequence Analysis and Tissue Distribution of the Mouse and Rat Urotensin II Precursors”, FEBS Letters, 1999, 457(1), pp. 28-32.
Cull et al., “Screening for Receptor Ligands Using Large Libraries of Peptides Linked to the C Terminus of thelacRepressor”, Procedure National Academy of Sciences, USA, 1992, 89, pp. 1865-1869.
Douglas, et al., “Differential Vasoconstrictor Activity of Human Urotensin-Il in Vascular Tissue Isolated from the Rat, Mouse, Dog, Pig, Marmoset and Cynomolgus Monkey”, British Journal of Pharmacology, 2000, 131(7): 1262-74.
Douglas et al., “From ‘Gills to Pills’: Urotensin-II as a Regulator of Mammalian Cardiorenal Function”, Trends in Pharmacological Sciences, 2004, 25(2), pp. 76-85.
Elshourbagy et al., “Molecular and Pharmacological Characterization of Genes Encoding Urotensin-II Peptides and Their Cognate G-Protein-Coupled Receptors from the Mouse and Monkey, British Journal of Pharmacology”, 2002, 36, pp. 9-22.
Fodor et al., “Multiplexed Biochemical Assays with Biological Chips”, Nature, 1993, 364, pp. 555-556.
Gardiner, et al., “Depressor and Regionally-Selective Vasodilator Effects of Human and Rat Urotensin II in Conscious Rates”, British Journal of Pharmacology, 2001, 132(8), pp. 1625-1629.
Gardiner, et al., “Bolus Injection of Human Ull in Conscious Rats Evokes a Biphasic Haemodynamic Response”, British Journal of Pharmacology, 2004, 143(3), pp. 422-430.
Gray et al., “Human Urotensin II Increases Coronary Perfusion Pressure in the Isolated Rat Heart Potentiation by Nitric Oxide Synthase and Cyclooxygenase Inhibition”, Life Sciences, 2001, 69(2), pp. 175-180.
Hassan, et al., “Effect of Human Urotensin-II Infusion on Hemodynamics and Cardiac Function1,2”, Canadian Journal of Physiol. Pharmacology, 2003, 81(2), pp. 125-128.
Houghten, et al., “The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides”, Biotechniques, 1992, 13, pp. 412-421.
Katano, et al., “Vasodilator Effect of Urotensin II, One of the Most Potent Vasoconstricting Factors, on Rat Coronary Arteries”, European Journal of Pharmacology, 2000, 402(1-2) pp. 209-211.
Lam, et al., “A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity”, Nature, 1991, 354, pp. 82-84.
Lam, et al., “Application of Combinatorial Library Methods in Cancer Research and Drug Discovery”, Anti-Cancer Drug Design, 1997, 12, pp. 145-167.
Lin et al., “Central Cardiovascular Action of Urotensin II in Conscious Rats”, Journal of Hypertension, 2003, 21(1), pp. 159-165.
Maguire et al., “Orphan-Receptor Ligand Human Urotensin II:Receptor Localization in Human Tissues and Comparison of Vasoconstrictor Responses with Endothelin-1”, British Journal of Pharmacology, 2000, 131(3), pp. 441-446.
Marchese, et al., Cloning and Chromosomal Mapping of Three Novel Genes, GPR9, GPR10, and GPR14, Encoding Receptors Related to Interleukin 8, Neuropeptide Y, and Somatostatin Receptors, Genomics, 1995, 29, pp. 335-344.
Ohsako, et al., “Cloning and Sequence Analysis of cDNAs Encoding Precursors of Urotensin II-a and -y”, The Journal of Neuroscience, 1986, 6, pp. 2730-2735.
Patacchini, et al., “Urantide: an Ultrapotent Urotensin II Antagonist Peptide in the Rat Aorta”, British Journal of Phrmacology, 2003, 140(7), pp. 1155-1158.
Russell, “Emerging Roles of Urotensin-II in Cardiovascular Disease”, Pharmacology & Therapeutics, 2004, 103, pp. 223-243.
Scott, et al., “Searching for Peptide Ligands with an Epitope Library”, Science, 1990, 249, pp. 386-390.
Sugo, et al., “Identification of Urotensin II-related Peptide as the Urotensin II-Immunoreactive Molecule in the Rat Brain”, Biochemical and Biophysical Research Communications, 2003, 310, pp. 860-868.
Turenne, et al., An Animal Model of Nicotinic-Acid-Induced Vasodilation: Effect of Halpperidol, Caffeing and Nicotine Upon Nicotonic Acid Response, 2001, 50(3), pp. 191-197.
Zhang, et al., “Urotensin II is a Nitric Oxide-Dependent Vasodilator and Natriuretic Peptide in the Rat Kidney”, American Journal of Physiology Renal Physiology, 2003, 285, F792-F798.
Zuckermann, et al., Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)Glycine Peptoid Library, Journal of Med. Chem., 1994, 37, pp. 2678-2685.
Andrade-Gordon Patricia
Colburn Raymond
Damiano Bruce
Minor Lisa
Qi Jian-shen
Hartley Michael G
Janssen Pharmaceutica NV
Samala Jagadishwar R
LandOfFree
Method of measuring the biological activity of an urotensin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of measuring the biological activity of an urotensin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of measuring the biological activity of an urotensin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670126